Bicycle Therapeutics Limited Stock Price, News & Analysis

Bicycle Therapeutics (NASDAQ: BCYC) reported Q3 2025 updates and financials on Oct 30, 2025. The company said it expects an update on dose selection for the Phase 2/3 Duravelo-2 trial and a potential approval pathway for zelenectide pevedotin in metastatic urothelial cancer after regulatory meetings in 1Q 2026. Ongoing trials Duravelo-3 (NECTIN4-amplified breast cancer) and Duravelo-4 (NECTIN4-amplified NSCLC) are open and enrolling. Clinical and imaging data for Bicycle Radioconjugates were presented at EANM and ESMO 2025. Board and Research Advisory appointments were announced to strengthen oncology expertise. Cash and cash equivalents were $648.3M as of Sept 30, 2025, with the company stating runway into 2028.

Bicycle Therapeutics (NASDAQ: BCYC) has strengthened its Board of Directors with two significant appointments in pharmaceutical leadership. Roger Dansey, M.D., former interim chief oncology officer at Pfizer and ex-CMO of Seagen, joins alongside Hervé Hoppenot, former chairman and CEO of Incyte.

Dr. Dansey brings extensive experience in drug development, having contributed to several successful cancer therapies including Keytruda and Adcetris. Under Hoppenot's leadership, Incyte grew revenues from $350 million to $4.2 billion and expanded its clinical pipeline. Both appointments bring valuable oncology research, drug development, and commercialization expertise to Bicycle's board as the company advances its proprietary bicyclic peptide technology platform.

Bicycle Therapeutics (NASDAQ: BCYC) reported Q2 2025 financial results and business updates. The company announced a strategic cost realignment including a 30% reduction in operations, primarily through workforce reductions. Key financial metrics include cash position of $721.5 million as of June 30, 2025, with runway extended into 2028, and a net loss of $79.0 million ($1.14 per share).

The company continues advancing its pipeline, with the Phase 1/2 Duravelo-4 trial for zelenectide pevedotin in NECTIN4-amplified non-small cell lung cancer now recruiting patients. Bicycle strengthened its leadership by adding Charles Swanton to its Board of Directors and forming a new Research and Innovation Advisory Board. The company expects key program updates in H2 2025, including EphA2 human imaging data and updates on the Duravelo-2 trial following FDA meetings.

Rice Biotech Launch Pad has appointed Carolyn Ng, a business unit partner at TPG Life Sciences Innovations, to its external advisory board. Ng brings significant expertise in biotech and company building, with extensive experience guiding early to midstage companies across various therapeutic areas.

Currently leading investments at TPG Life Sciences Innovations in San Francisco, Ng serves on multiple boards including Mbrace Therapeutics, Adcendo Aps, and Bicara Therapeutics (NASDAQ: BCAX). Her appointment marks her as the 16th member of the Launch Pad's external advisory board, joining leaders from various prestigious institutions and companies.

The Rice Biotech Launch Pad, based in Houston, focuses on accelerating the translation of Rice University's health and medical technology discoveries into practical medical solutions.

Bicycle Therapeutics (NASDAQ: BCYC) announced the granting of inducement awards to eight new employees on July 1, 2025. The awards consist of non-qualified share options to purchase a total of 77,400 ordinary shares at an exercise price of $6.95 per share.

The options were granted under Bicycle's 2024 Inducement Plan and will vest over four years, with 25% vesting after one year and the remaining shares vesting monthly over the following 36 months. The grants were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Bicycle Therapeutics (NASDAQ: BCYC) announced the granting of inducement awards to seven new employees on June 2, 2025. The awards consist of non-qualified share options to purchase 57,700 ordinary shares under the company's 2024 Inducement Plan. The options have an exercise price of $8.22 per share, based on the company's closing price on May 30, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months, contingent on continued employment. These grants were approved by the Compensation Committee as inducement material for new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

Bicycle Therapeutics (NASDAQ: BCYC) announced two poster presentations at the upcoming 2025 ASCO Annual Meeting in Chicago from May 30-June 3. The first presentation will share preliminary results from the Phase 1/2 Duravelo-1 study of zelenectide pevedotin (BT8009) combined with pembrolizumab in treating previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. The second poster will present a phase 2/3 study (Duravelo-2) of BT8009 targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer. Both presentations are scheduled for Monday, June 2, and will be available on the company's website.

Bicycle Therapeutics (NASDAQ: BCYC) announced the granting of inducement awards to 13 new employees on May 1, 2025. The awards consist of non-qualified share options to purchase a total of 79,500 ordinary shares at an exercise price of $8.56 per share, which was the company's closing price on April 30, 2025.

The options will vest over a four-year period, with 25% vesting after one year and the remaining balance vesting monthly over the subsequent 36 months. These grants were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Bicycle Therapeutics (NASDAQ: BCYC) reported Q1 2025 financial results and business updates. The company ended Q1 with $793.0 million in cash, providing runway into 2H 2027. Key highlights include: multiple abstracts accepted at ASCO and AACR meetings, ongoing recruitment for Phase 1/2 Duravelo-3 trial for zelenectide pevedotin in NECTIN4-amplified breast cancer, and new leadership appointments. Financial results show R&D expenses increased to $59.1 million (up from $34.9M in Q1 2024), while net loss widened to $60.8 million ($0.88 per share). The company continues to advance its oncology pipeline, with dose selection for the Phase 2/3 Duravelo-2 trial in metastatic urothelial cancer expected in 2H 2025. Additionally, promising MT1-MMP imaging data was presented at AACR, validating their Bicycle® Radioconjugate technology.